EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
admin 13th September 2017 Uncategorised 0LISBON, Portugal—Back in 2015, Boehringer Ingelheim and Eli Lilly were the first drugmakers to show that a diabetes med could cut the risk of cardiovascular death, and they’re still working to capitalize on that advantage.
More: EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
Source: fierce